The SGN35-032 phase II study further explored the efficacy of brentuximab in non-ALCL T-cell lymphomas with less than 10% CD30 expression, categorising patients into two subgroups: CD30 < 1% and CD30 1–10%. Here, TNFRSF8 is linked to T-cell non-Hodgkin lymphoma.